How Two Former IT Industry Professionals Found their Calling as Gene Therapy CEOs

Published on :

How Two Former IT Industry Professionals Found their Calling as Gene Therapy CEOs  By Chris Frew | November 22, 2023 In most cases, the prerequisites for the CEO of a [….]

Addimmune Prepares to Go Public, Initiate Phase Ib HIV Trial

Published on :

The Rockville-based company, an anticipated SPAC merger of American Gene Technologies HIV business and a 10x Capital Venture Acquisition Corp. III, will list on the New York Stock Exchange under the ticker symbol HIV. The company will have a valuation of $500 million. Funds will be used to advance clinical development of Addimmune’s cell therapy for HIV. 

“DNA Valley” Continues to Flourish in Maryland, the Birthplace of the Human Genome Project

Published on :

Jeff Galvin, the CEO of American Gene TechnologiesⓇ, one of the leading biotech companies in Maryland, has championed the state as “DNA Valley.” And Galvin should know: he came to Maryland after a successful career in Silicon Valley and sees parallels between the early days of an emerging Silicon Valley and what’s going on today in DNA Valley, which currently stretches from Montgomery County and Frederick, Maryland all the way up to Baltimore.

​​HIV Functional Cure Momentum Builds as American Gene Technologies Approaches Data Readout

Collage of photos of AGT employees, scientists in the lab, and the AGT office building
Published on :

After achieving several important clinical milestones, momentum and excitement has been building for months around the company’s lead pipeline candidate AGT103-T, which is a potential HIV functional cure. In the coming months, the company expects to have the latest data readout for its Phase I trial. AGT103-T is a single-dose HIV gene therapy that could potentially replace antiretroviral therapy (ART) with a functional cure.

Dr. Anthony Fauci & AGT’s Jeff Galvin Join ‘I AM BIO’ to Discuss Future of HIV Treatments

Published on :

EPISODE SUMMARY
For more than a year now, COVID has been society’s focus—and rightly so. But today we turn our attention to another virus—HIV. After 40 years, there is still no cure or a vaccine for the disease. In this episode, we hear from Dr. Anthony Fauci and CEO of innovative company American Gene Technologies, Jeff Galvin, about the past, present, and future of HIV treatments and medications. Is there a cure on the horizon?
Guests:
Jeffrey Galvin, American Gene Technologies
Anthony Fauci, National Institute of Allergy and Infectious Diseases
EPISODE NOTES
For more than a year now, COVID has been society’s focus—and rightly so. But today we turn our attention to another virus—HIV. After 40 years, there is still no cure or a vaccine for the disease. In this episode, we hear from Dr. Anthony Fauci and CEO of innovative company American Gene Technologies, Jeff Galvin, about the past, present, and future of HIV treatments and medications. Is there a cure on the horizon?  

Regenerative Medicine Leaders Emphasized a Focus on Efficiencies and Collaboration to Make a Greater Impact on Patients

Published on :

Regenerative Medicine Leaders Emphasized a Focus on Efficiencies and Collaboration to Make a Greater Impact on Patients “We are here to bring the Community together to change the world!” opened [….]